Semaglutide

NgoDisemba 2017, i-US Food and Drug Administration (FDA) ivume uluhlu lwe-Smeglugan peptide injection kulawulo lokutya oluncedisayo kunye nokuzivocavoca ukuphucula ukulawulwa kwe-glucose yegazi kwizigulane ezine-2 yeswekile.Ukongeza, i-Novo kunye ne-Nord ziphinde zaphuhlisa uhlobo lwedosi yomlomo i-Rybelsus ye-Smeglugin, kwaye yamkelwa okokuqala yi-FDA ngoSeptemba 2019. Eli liyeza lokuqala elivunyiweyo lomlomo le-GLP-1.isifo seswekile.Ngokwenyani, i-Smeglugin lichiza le-hypoglycemic, kodwa ngenxa yokuba iziyobisi ezinjenge-Smeglugin peptide zinokucothisa isisu esingenanto kwaye zicinezele umdla wokutya, ziyakunciphisa ubunzima.

Ukujonga oku, ngoJuni ka-2021, i-FDA yavuma ngokusemthethweni ulawulo lobunzima bexesha elide lokutyeba okanye ukutyeba kwabantu abadala.Abantu abasebenzayo ngaba: izigulane ezilula kunye ne-BMI ≥30 kg / m2;kunye ne-BMI> 27 kg / m2 kunye nokudibanisa ubuncinane enye ingxaki yokutyeba, efana noxinzelelo lwegazi, uhlobo lwe-2 yeswekile, okanye i-lipids yegazi engaqhelekanga.Yayikwayile mvume yokuba umfuziselo wangcwatywa kwi-Smeglugin kwindlela "yeyeza lomlingo lokunciphisa ubunzima".

Ngo-Epreli 2021, i-Smegugan yamkelwa e-China yokulawula iswekile yegazi kwizigulane ezinesifo seswekile se-2 (T2DM).Nangona isalathisi sokulahlekelwa kwesisindo asivunywanga e-China, imfuno yokulahlekelwa kwesisindo sasekhaya ayikwazi ukubanjelwa e-China.Ukongeza, umxholo ophambili othi "ukubhitya kunye nokuncipha", kwisiqingatha sesibini sika-2022, i-peptide ye-Smeglugin "ayizange ivume" kwintsimi yokunciphisa umzimba., Kanye kwiiplatifti ezininzi ze-e-commerce, iye yaqalisa i-boom ekuthengeni, kwaye yakha yaba yixabiso eliphezulu "ngaphandle kwe-stock king", eyakhokelela ngokuthe ngqo kwiingxaki zokuvelisa abavelisi kunye nokubonelela.UNuo noNord's kaJulayi kulo nyaka uphelileyo bathi Ukuqaliswa kwakhona kokunikezelwa kweziyobisi kuya kumisa unikezelo lweemarike ezingaphandle kwesibhedlele.

Ukuthandwa kwe-peptide ye-Smegugu kuye kwaqinisekiswa kwakhona kwidatha yemali ye-Nuo kunye ne-Nord.Ngokweziphumo zamva nje zika-2022 ezibhengezwe nguNuo noNord, ingeniso yonyaka yeshishini le-Nuo kunye ne-Nord ye-GLP-1 yayiyi-83.371 yebhiliyoni yeDan Ying Crown (elingana ne-81.6 yeebhiliyoni zeeyuan), ukwanda kwe-56% ngonyaka.Phakathi kwazo, intengiso ye-Smeglugin ibizibhiliyoni ezingama-59.75 zeDan Ying Crown (elingana ne-58.5 yeebhiliyoni zeeyuan), ukwanda kwe-77% ngonyaka.Ukusebenza kwentengiso yeemveliso ze-GLP-1 kwicandelo lonyango lwe-2 yeswekile e-China yonyuke nge-102% kuDan Ying Krone.

Ewe kunjalo, ukuqhuma kwe-Smeglugin kwintsimi yokunciphisa umzimba kuhambelana ngokusondeleyo nempembelelo yayo ebalulekileyo."Lixesha lokutya, ukusela nokusela, ukuthatha iipounds ezi-5 zobunzima, ulahlekelwe iipounds ezingama-30 ngoJanuwari" njalo njalo.Ukongeza, "ukulala tyaba" kunokuba mncinci, nto leyo eye yatsala amehlo angenakubalwa kwi-Smegtu peptides, eyayisaziwa ngokuba "liyeza lomlingo lokunciphisa ubunzima".Nangona kunjalo, abanye oogqirha baye bathi i-Simei Gulu peptide ine-2/3 yeentengiso zasekhaya e-China ukuze unciphise umzimba, kungekhona isifo seswekile.Ngakolunye uhlangothi Ngokubhekiselele kwi-peptide ye-Smeglugan njengeyeza likagqirha, kukho iingozi ezifihliweyo kukhuseleko lweziyobisi eziphezulu.

Kubalulekile ukuqaphela ukuba izigqibo zophando lwasekhaya zamayeza anjalo zivela kwizigulana ezinkulu zokutyeba kwabantu abadala.Kubantu abanamafutha amancinci okanye ubunzima obuqhelekileyo (BM <27kg / m2), izibonelelo kunye neengozi ezinokwenzeka azikaziwa.Ukongezelela, ukongeza kwiimpendulo ze-hypoglycemia ezibangelwa iziyobisi ze-hypogenal ezenzeka kwiziyobisi ze-hypoglycemic, iimpendulo zesisu zivelele, kwaye iziganeko ze-nausea, ukuqunjelwa, ukuhlanza kunye nohudo ziphezulu kwi-82.8%.7%.Eyona nto ibalulekileyo kukuba i-Smeglugin ayivunywanga kwizalathiso zokuncipha kwesisindo eTshayina.Ingxaki yamajelo amayeza kunye nokusetyenziswa kweziyobisi kwabantu abanjalo kufanelekile ukuhoywa.